Expertise in
18
conditions

Dr. Gary Falk

Gastroenterology
University Of Pennsylvania
3400 Civic Center Blvd, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
University Of Pennsylvania
3400 Civic Center Blvd, 
Philadelphia, PA 

Overview

Gary Falk is a Gastroenterologist in Philadelphia, Pennsylvania. Dr. Falk is highly rated in 18 conditions, according to our data. His top areas of expertise are Barrett Esophagus, Eosinophilic Esophagitis, Esophagitis, Gastritis, and Endoscopy.

His clinical research consists of co-authoring 222 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

University of Pennsylvania
3400 Civic Center Blvd, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
Enrollment Status: Recruiting
Publish Date: September 12, 2025
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 2
Study of Compliance, Practice Patterns, and Barriers REgarding Established National Screening Programs for Barrett's Esophagus: SCREEN-BE
Study of Compliance, Practice Patterns, and Barriers REgarding Established National Screening Programs for Barrett's Esophagus: SCREEN-BE
Enrollment Status: Completed
Publish Date: October 22, 2025
Intervention Type: Behavioral
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Application of the Microbiome and Microenvironment to Novel Non-Endoscopic Screening and Surveillance in Barrett's Esophagus
Application of the Microbiome and Microenvironment to Novel Non-Endoscopic Screening and Surveillance in Barrett's Esophagus
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Device
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus
Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus
Enrollment Status: Unknown
Publish Date: August 03, 2022
Intervention Type: Device
Study Phase: Not Applicable
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Enrollment Status: Completed
Publish Date: September 28, 2021
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Enrollment Status: Completed
Publish Date: May 26, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 11 Less Clinical Trials

222 Total Publications

Colibactin-producing E. coli promote carcinogenesis of gastroesophageal adenocarcinoma and simultaneously induce autophagy and differentiation.
Colibactin-producing E. coli promote carcinogenesis of gastroesophageal adenocarcinoma and simultaneously induce autophagy and differentiation.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Similar Doctors
Gary R. Lichtenstein
Expertise in
17
conditions
Dr. Gary R. Lichtenstein
Gastroenterology
Expertise in
17
conditions
Dr. Gary R. Lichtenstein
Gastroenterology

Perelman Center For Advanced Medicine South Pavilion

3400 Civic Center Boulevard, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-349-8222
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gary Lichtenstein is a Gastroenterologist in Philadelphia, Pennsylvania. Dr. Lichtenstein is highly rated in 17 conditions, according to our data. His top areas of expertise are Ulcerative Colitis, Viral Gastroenteritis, Crohn's Disease, Endoscopy, and Colonoscopy. Dr. Lichtenstein is currently accepting new patients.

Thomas E. Kowalski
Expertise in
33
conditions
Dr. Thomas E. Kowalski
Gastroenterology | Hepatology
Expertise in
33
conditions
Dr. Thomas E. Kowalski
Gastroenterology | Hepatology
132 South 10th Street, 
Philadelphia, PA 
 (1.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Kowalski is a Hepatologist and a Gastroenterologist in Philadelphia, Pennsylvania. Dr. Kowalski is highly rated in 33 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Jaundice, Pancreatic Pseudocyst, Endoscopy, and Gastric Bypass. Dr. Kowalski is currently accepting new patients.

Expertise in
29
conditions
Dr. Gregory G. Ginsberg
Gastroenterology
Expertise in
29
conditions
Dr. Gregory G. Ginsberg
Gastroenterology

Penn Gastroenterology Perelman

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-349-8222
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gregory Ginsberg is a Gastroenterologist in Philadelphia, Pennsylvania. Dr. Ginsberg is highly rated in 29 conditions, according to our data. His top areas of expertise are Barrett Esophagus, Achalasia, Cholestasis, Endoscopy, and Colonoscopy. Dr. Ginsberg is currently accepting new patients.

Frequently Asked Questions about Dr. Gary Falk

How do I make an appointment with Dr. Gary Falk?

You can book an appointment with Dr. Gary Falk by calling their office at 215-349-8222. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gary Falk a top-rated expert for Barrett Esophagus?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gary Falk is classified as an Elite expert for Barrett Esophagus, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gary Falk specialize in?

While Dr. Gary Falk is a Gastroenterology, they have specific expertise in Barrett Esophagus, Eosinophilic Esophagitis, and Esophagitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Gary Falk participate in research or clinical trials?

Yes. Dr. Gary Falk has published 222 articles and abstracts on conditions like Barrett Esophagus. You can view a list of Dr. Gary Falk's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gary Falk accept my insurance?

Dr. Gary Falk accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-349-8222 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Falk's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile